Developing a new method for male contraception using CatSper inhibitors
Official title: Catsper Inhibitors for Male Contraception
Funded at University of Minnesota · NIH-11016977 · Data updated 2026-11-12
This study is looking for new ways for men to prevent pregnancy by finding safe compounds that can slow down sperm movement, making it easier to control when to have kids.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | February 1, 2024 |
| Project end | January 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $375,000 |
| NIH project number | 5R61HD114221-02 |
| Project ID | NIH-11016977 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men who are seeking contraceptive options and are interested in participating in clinical trials.
✕Less likely to help
Patients who are not interested in male contraception or those who have conditions affecting sperm production may not benefit from this research.
What this research studies
This research focuses on creating a new form of male contraception by targeting the CatSper ion channel, which is essential for sperm function and male fertility. The study will involve screening various compounds to find those that can effectively inhibit CatSper, thereby reducing sperm motility and preventing pregnancy. Researchers will conduct tests to ensure these compounds are safe and effective, including assessing their pharmacokinetic properties and potential side effects. If successful, this approach could provide a reliable and reversible contraceptive option for men.
Why it matters
Potential benefit: If successful, this research could lead to a new, effective, and reversible male contraceptive method.
How similar studies have gone: Previous research has shown promise in targeting ion channels for contraception, but this specific approach using CatSper inhibitors is relatively novel.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Georg, Gunda I. — University of Minnesota
- Study coordinator: Georg, Gunda I.
Related research
Other NIH-funded projects on the same topics.
-
Mobile health support to boost PrEP and contraception use among young women in Zambia
A mobile health program helps female university students in Zambia learn about and access HIV prevention and contraception.
-
Blocking CFTR in the cervix to prevent conception without hormones
A non-hormonal approach aims to stop sperm from entering the uterus by making cervical mucus too thick for sperm, potentially offering a new contraception option.
-
Long‑lasting antibody vaginal ring for non‑hormonal birth control
Testing a vaginal ring that slowly releases an antibody to trap sperm and prevent pregnancy for people seeking non‑hormonal contraception.
-
A woman-controlled, nonhormonal on-demand contraceptive device
This project is creating a woman-controlled vaginal device that releases a fabric-like polymer which thickens on contact with semen to help prevent pregnancy.
-
Vaginal ring releasing non-hormonal antibody contraception for month-long use
A monthly vaginal ring delivers a non-hormonal antibody-based contraceptive, offering a convenient, user-controlled option for women who want to avoid daily dosing or invasive procedures.
-
On-demand non-hormonal vaginal contraception with a fast-dissolving antibody tablet
A new on-demand vaginal tablet dissolves quickly to release a monoclonal antibody for non-hormonal contraception.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.